Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03240861 · ClinicalTrials.gov registry record · Phase 1
Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer
A Phase 1 study, sponsored by Jonsson Comprehensive Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT03240861 is a Phase 1 study that was terminated before completion, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 5 participants.
The verdict
NCT03240861, a Phase 1 study, was terminated before completion, sponsored by Jonsson Comprehensive Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This phase I clinical trial evaluates the safety and feasibility of administering NY-ESO-1 TCR (T cell receptor)engineered peripheral blood mononuclear cells (PBMC) and peripheral blood stem cells (PBSC) after a myeloablative conditioning regimen to treat patients with cancer that has spread to other parts of the body. The conditioning chemotherapy makes room in the patient?s bone marrow for new blood cells (PBMC) and blood-forming cells (stem cells) to grow. Giving NY-ESO-1 TCR PBMC and stem cells after the conditioning chemotherapy is intended to replace the immune system with new immune cells that have been redirected to attack and kill the cancer cells and thereby improve immune system function against cancer.
Interventions
- PROCEDURE Computed Tomography
- DRUG Busulfan
- BIOLOGICAL Aldesleukin
- OTHER 18F-FHBG
- BIOLOGICAL Cellular Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2017-07-26 |
| Est. Completion | 2023-10-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03240861
The ClinicalTrials.gov registry entry for NCT03240861 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Computed Tomography is the first listed.
NCT03240861 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03240861 about?
NCT03240861 is a clinical study titled "Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer". This phase I clinical trial evaluates the safety and feasibility of administering NY-ESO-1 TCR (T cell receptor)engineered peripheral blood mononuclear cells (PBMC) and peripheral blood stem cells (PBSC) after a myeloablative conditioning regimen to treat patients with cancer that has spread to othe...
What is the current status of trial NCT03240861?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2017-07-26. Estimated completion is 2023-10-19.
What interventions are being tested in trial NCT03240861?
The interventions under investigation include: Computed Tomography (PROCEDURE), Busulfan (DRUG), Aldesleukin (BIOLOGICAL), 18F-FHBG (OTHER), Cellular Therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT03240861?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.